sintilimab,anlotinib
eli lilly,Innovent Biologics,advenchen,sino biopharmaceuticals
['sintilimab', 'anlotinib']
primary endpoint of rr favors sintilimab + anlotinib (50% vs 33%). dor 16.3 vs 6.2m and pfs hr 0.40. no trae leading to discontinuation with sintilimab + anlotinib and overall well tolerated. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him